Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
Submitted by
admin
on September 28, 2018 - 10:34am
Source:
CP Wire
News Tags:
Alnylam
Patisiran
Onpattro
Japan
hATTR amyloidosis
Headline:
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
snippet:
Patisiran is approved in the US for hATTR
It has orphan drug status in the US and Japan
Patisiran is elegible for priority review in Japan
Do Not Allow Advertisers to Use My Personal information
